September’s pain management coverage examined postoperative nonopioid options, lessons from sickle cell pain research, and pharmacists’ experiences with controlled-substance prescribing.
Publication|Articles|May 14, 2024
Pharmacy Practice in Focus: Health Systems
- May 2024
- Volume 13
- Issue 3
Implementation of a Pharmacist-Led COPD Transitions of Care Service
A pharmacist-led transitions of care program reduced chronic obstructive pulmonary disease readmissions by implementing guideline-based inhaler prescribing and addressing medication adherence barriers, decreasing 30-day readmission rates.
Advertisement
Advertisement
Background
Related to this article
FDA clears tiratricol for MCT8 deficiency, lowering dangerous T3 and outlining dosing, lab testing, and pharmacy access.
A single infusion reversed new-onset type 1 diabetes (T1D) in more than half of treated mice by strengthening regulatory T cells and driving autoreactive CD8+ T cells into a less destructive state.
Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
In a Pharmacy Times interview, study coauthor William J. Peppard, PharmD, discusses the association between suzetrigine and fewer opioid refills after knee replacement, the limits of the evidence, and the access barriers pharmacists can help patients navigate.
The once-daily tablet is the third approved treatment for fibrodysplasia ossificans progressiva (FOP), with CYP3A4 and metformin interaction guidance.
Marissa Reigelman of US Pharmacopeia explains how single-country dependence on key starting materials, combined with low prices, has kept 5 critical injectable drugs in shortage for more than a decade.
An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-fourths of treated patients.
Advertisement
Advertisement